
21 March 2018Americas
J&J plans to sell LifeScan for $2.1bn
Johnson & Johnson (J&J) has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Europe
14 September 2018 Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.
Big Pharma
22 February 2018 Johnson & Johnson has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.
Editor's picks
Editor's picks
Europe
14 September 2018 Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.
Big Pharma
22 February 2018 Johnson & Johnson has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.
Europe
14 September 2018 Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.
Big Pharma
22 February 2018 Johnson & Johnson has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.